New combo therapy tackles cancer in HIV patients
NCT ID NCT04514484
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and cabozantinib
- What this could lead to
- If it works, this could point toward a treatment option for people with HIV who have advanced cancers.
- What could go wrong
- This is a very early, small pilot trial with only 8 participants. It mainly checks safety, not effectiveness, and may not lead to a standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Fasting during chemo: a new way to boost treatment?